Fateeva V V, Shumakher G I, Vorob'eva E N, Khoreva M A, Voskanyan L R
Sechenov First Мoscow State Medical University, Moscow, Russia.
Altai State Medical University, Barnaul, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2):32-37. doi: 10.17116/jnevro20171172132-37.
To evaluate the efficacy and safety of divazа in the treatment of cognitive and emotional disorders in patients with chronic cerebral ischemia (CCI) based on clinical findings and laboratory markers of endothelial dysfunction.
Thirty patients with CCI, aged 40 to 70 years, were examined. All patients were treated with divazа (2 tablets 3 times a day) for 12 weeks. Cognitive functions and markers of endothelial dysfunction (the activity of endothelial NO-synthase (eNOS), the number of circulating desquamated endothelial cells in blood plasma) were measured at baseline and after treatment.
Divazа significantly reduced the severity of clinical symptoms and had a positive effect on endothelial dysfunction normalizing the tone of cerebral vessels and preventing deendotheliazation.
The use of divazа resulted in clinical improvement and normalization of markers of endothelial dysfunction as well.
基于内皮功能障碍的临床发现和实验室指标，评估地伐唑治疗慢性脑缺血（CCI）患者认知和情感障碍的疗效及安全性。
对30例年龄在40至70岁的CCI患者进行检查。所有患者接受地伐唑治疗（每日3次，每次2片），疗程为12周。在基线期及治疗后测量认知功能和内皮功能障碍指标（内皮型一氧化氮合酶（eNOS）活性、血浆中循环脱落内皮细胞数量）。
地伐唑显著减轻临床症状的严重程度，并对内皮功能障碍产生积极影响，使脑血管张力正常化并防止内皮剥脱。
使用地伐唑可使临床症状改善，同时内皮功能障碍指标也恢复正常。
